Display Single Record

FOI Request

Disclosure ID
FOI/02664
Request Date
August 20, 2018
Subject
Viscosupplementation 2
Description
  1. Does your organisation use/perform Viscosupplementation injections?
  2. How much has your organisation spent in the financial year 2017/18 on Viscosupplementation on each product out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20)
  3. Which brand(s) Viscosupplemenetation have been used in the financial year 2017/18 out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20)
  4. Which brand(s) Viscosupplementation do you have listed on the hospital formulary out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20)
  5. Which departments in your hospital use Viscosupplementation?
  6. What is your current pathway for knee osteoarthritis patients
  7. Do you have a community MSK service, if yes who is that contracted to?
  8. What is the current waiting list for Total Knee Replacement in your organisation for the financial year 2017/18
  9. Has the organisation incurred any fines for breach of the Total Knee Replacement waiting list in 2017/18
Response
1 Does your organisation use/perform Viscosupplementation injections? Yes
2 How much has your organisation spent in the financial year 2017/18 on Viscosupplementation on each product out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20) This information is exempt under section 43(2) of the Freedom of Information Act 2000 as disclosure would prejudice the commercial interests of the Trust.
3 Which brand(s) Viscosupplemenetation have been used in the financial year 2017/18 out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20) From Pharmacy Hylan G-F 24mg/6ml and Hylan G-F 48mg/6ml
4 Which brand(s) Viscosupplementation do you have listed on the hospital formulary out of the following list: Arhtrum H, Cingal, Durolane, Euflexxa, Fermathron, Orthovisc, Ostenil, Ostenil Plus, RenehaVis, Suplasyn, Synocrom, Synocrom Mini, Synolis, Monovisc, Synopsis, Synvisc (Hylan G-F20), Synvisc ONE (Hylan G-F20) Now using Ostenil via pharmacy
5 Which departments in your hospital use Viscosupplementation? Theatres, Maxilo-facial, orthopaedic
6 What is your current pathway for knee osteoarthritis patients Our current pathway for knee osteoarthritis management of the patients is established protocol as recognised by AAOS and BOA using conservative management of the patient firstly with analgesia, physiotherapy, cortisone and HA injections, pain management clinic assessment and if everything fails then they are offered knee replacements.
7 Do you have a community MSK service, if yes who is that contracted to? Yes. Nick Lane, Head of Therapies.
8 What is the current waiting list for Total Knee Replacement in your organisation for the financial year 2017/18 210 patients currently waiting as of today (17/9/18)
9 Has the organisation incurred any fines for breach of the Total Knee Replacement waiting list in 2017/18 No
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6